胃癌免疫治疗的预后生物标志物
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v7i3.14434
Abstract
胃癌(Gastric Cancer,GC)是一种高度异质性的恶性肿瘤,随着免疫检查点抑制剂等免疫疗法在临床中的应用,部分患者获得了显著疗效,然而,如何筛选出最可能从这些治疗中受益的患者仍然是一个挑战。本文旨在系统性地回顾最新的研究进展,介绍用于预测胃癌免疫治疗效果的各种预后生物标志物,并探讨这些标志物与治疗效果及免疫不良反应的具体关系,总结出许多能预测胃癌免疫治疗疗效的生物标志物并分析了它影响疗效的可能机制,并归纳出胃癌免疫不良反应相关的预测标志物。
Keywords
免疫检查点抑制剂；免疫治疗；胃癌；免疫不良反应；标志物
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] 彭浩欣,王雅坤,陈杨.2024年度胃癌治疗现状与问题[J].肿瘤综合治疗电子杂志,2025,11(02):1-14.
[2] FUCHS C S,DOI T,JANG R W,et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Trea ted Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial [J]. JAMA Oncol, 2018, 4(5):e180013.
[3] KIM S T,CRISTESCU R, BASS A J,et al.Comprehensive mole cular characterization of clinical responses to PD-1 inhibiti on in metastatic gastric cancer[J].Nat Med,2018,24(9):1449-58.
[4] WANG F, WEI X L, WANG F H, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432[J].Ann Oncol,2019,30(9):1479-86.
[5] ZHANG J,WANG L,ZHANG S,et al.Alpha-fetoprotein predic ts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients[J].BMC Cancer,2024,24(1):266.
[6] YUE C,JIANG Y,LI P,et al.Dynamic change of PD-L1 expre ssion on circulating tumor cells in advanced solid tumor pati ents undergoing PD-1 blockade therapy [J]. Oncoimmunology, 2018,7(7):e1438111.
[7] NOSE Y, SAITO T, KUROKAWA Y, et al. C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer [J]. BJC Rep,2023,1(1):7.
[8] TIAN B W,YANG Y F,YANG C C,et al.Systemic immune-inf lammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis [J]. Immunotherapy, 2022, 14(18):1481-96.
[9] Erratum for the Research Article "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunothera py" by R. Cristescu, R. Mogg, M. Ayers, A. Albright, E. Murphy,J.Yearley,X.Sher,X.Q.Liu,H.Lu,M.Nebozhyn,C.Zhang,J.K. Lunceford, A.Joe,J.Cheng,A.L.Webber, N. Ibrahim, E. R. Plimack, P. A. Ott, T. Y. Seiwert, A. Ribas, T. K. McClanahan, J. E. Tomassini, A. Loboda, D. Kaufman[J].Science,2019,363(6430).
[10] ZHU M,ZHANG L T,LAI W,et al.Prognostic value of inflam matory and nutritional indexes among patients with unresect able advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study [J].PeerJ,2024,12: e18659.
[11] LI X,WANG Y,ZHAI Z,et al.Predicting response to immun otherapy in gastric cancer via assessing perineural invasion -mediated inflammation in tumor microenvironment [J].J Exp Clin Cancer Res,2023,42(1):206.
[12] KOCH M R A, GONG R, FRIEDRICH V, et al. CagA-specific Gastric CD8(+) Tissue-Resident T Cells Control Helicobacter pylori During the Early Infection Phase [J]. Gastroenterology, 2023,164(4):550-66.
[13] XIE T,LIU Y,ZHANG Z,et al.Positive Status of EpsteinBarr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study[J].J Immunother,2020,43 (4):139-44.
[14] NI L, HUANG J, DING J, et al. Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis[J].Front Nutr,2022,9:823087.
[15] DING P,GUO H,SUN C,et al.Combined systemic immuneinflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study[J].BMC Gastroenterol,2022,22(1):121.
[16] WANG J, XIA W, HUANG Y, et al. A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer[J].Front Immunol,2022,13:1016612.
[17] MASUDA K, SHOJI H, NAGASHIMA K, et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab [J]. BMC Cancer,2019,19(1): 974.
[2] FUCHS C S,DOI T,JANG R W,et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Trea ted Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial [J]. JAMA Oncol, 2018, 4(5):e180013.
[3] KIM S T,CRISTESCU R, BASS A J,et al.Comprehensive mole cular characterization of clinical responses to PD-1 inhibiti on in metastatic gastric cancer[J].Nat Med,2018,24(9):1449-58.
[4] WANG F, WEI X L, WANG F H, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432[J].Ann Oncol,2019,30(9):1479-86.
[5] ZHANG J,WANG L,ZHANG S,et al.Alpha-fetoprotein predic ts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients[J].BMC Cancer,2024,24(1):266.
[6] YUE C,JIANG Y,LI P,et al.Dynamic change of PD-L1 expre ssion on circulating tumor cells in advanced solid tumor pati ents undergoing PD-1 blockade therapy [J]. Oncoimmunology, 2018,7(7):e1438111.
[7] NOSE Y, SAITO T, KUROKAWA Y, et al. C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancer [J]. BJC Rep,2023,1(1):7.
[8] TIAN B W,YANG Y F,YANG C C,et al.Systemic immune-inf lammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis [J]. Immunotherapy, 2022, 14(18):1481-96.
[9] Erratum for the Research Article "Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunothera py" by R. Cristescu, R. Mogg, M. Ayers, A. Albright, E. Murphy,J.Yearley,X.Sher,X.Q.Liu,H.Lu,M.Nebozhyn,C.Zhang,J.K. Lunceford, A.Joe,J.Cheng,A.L.Webber, N. Ibrahim, E. R. Plimack, P. A. Ott, T. Y. Seiwert, A. Ribas, T. K. McClanahan, J. E. Tomassini, A. Loboda, D. Kaufman[J].Science,2019,363(6430).
[10] ZHU M,ZHANG L T,LAI W,et al.Prognostic value of inflam matory and nutritional indexes among patients with unresect able advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study [J].PeerJ,2024,12: e18659.
[11] LI X,WANG Y,ZHAI Z,et al.Predicting response to immun otherapy in gastric cancer via assessing perineural invasion -mediated inflammation in tumor microenvironment [J].J Exp Clin Cancer Res,2023,42(1):206.
[12] KOCH M R A, GONG R, FRIEDRICH V, et al. CagA-specific Gastric CD8(+) Tissue-Resident T Cells Control Helicobacter pylori During the Early Infection Phase [J]. Gastroenterology, 2023,164(4):550-66.
[13] XIE T,LIU Y,ZHANG Z,et al.Positive Status of EpsteinBarr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study[J].J Immunother,2020,43 (4):139-44.
[14] NI L, HUANG J, DING J, et al. Prognostic Nutritional Index Predicts Response and Prognosis in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis[J].Front Nutr,2022,9:823087.
[15] DING P,GUO H,SUN C,et al.Combined systemic immuneinflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study[J].BMC Gastroenterol,2022,22(1):121.
[16] WANG J, XIA W, HUANG Y, et al. A vasculogenic mimicry prognostic signature associated with immune signature in human gastric cancer[J].Front Immunol,2022,13:1016612.
[17] MASUDA K, SHOJI H, NAGASHIMA K, et al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab [J]. BMC Cancer,2019,19(1): 974.
Copyright © 2025 保善茵, 张曼, 刘成娟, 马金华
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License